Thursday, August 24, 2017 8:41:14 AM
I found the article very fascinating it opens up one more of the trillion puzzles we need to decipher to understand the workings of the human body. From what I recall there was a Danish study that revealed genetic defects which caused either a lower or higher ( cant recall which one ) trig level which resulted in a higher or lower rate of CAD - suggesting direct correlation of Trigs and CAD.
Does this mean that Vascepa will be an automatic success in lowering CAD - hardly - from what I recall a recent study on PCSK9-s revealed that the reduction of atherosclerosis was not what was expected for the reduction in LDL . Look at NIacin it raises HDL and HDL was touted as being one of the strongest markers for CAD - no effect on CAD - Zetia initially shown to have no effect on CAD after reducing LDL - repeat study suggested mild benefit .... which of course gets into the whole issue of outcomes studies vs just looking at markers the role of inflammation in CAD etc etc
After practicing medicine for many years one point becomes clear - biological systems are immensely complex - controlling and isolating factors to determine cause and effect is extremely difficult. Whereas , in the electronic, mechanical perhaps even chemical world this is rather easy.
Absence or variation of a gene, resulting in variation in a marker chemical, may not necessarily be the direct correlation we believe it is for disease induction. That gene alteration may be having countless other effects that we are unable to identify - IN many ways we are the blind man who can only feel one part of the elephant - then run out insisting that the elephant is a snake because the only part we felt was the trunk. (Unfortunately, the guy upstairs who made us - never gave us the blueprints).
So this study is great news and perhaps it will lead to the development of a med that has success in lowering the incidence of CAD. However, let me perhaps reflect onto your own experience. WHen you hear about a great breakthrough for cancer - what do you think ?
Currently , I am very jaundiced about such claims - I have heard them for over 30 years. Perhaps there are great breakthroughs in our knowledge and understanding - yet the reality is - cancer has become the #1 killer and our progress is painfully slow as compared to CAD. ( OF course CAD was mainly a plumbing problem - open the pipes - Cancer is so much more complex)
The proof is in the pudding ...and the pudding is still in the oven .......
(dictated with Dragon Dictate excuse errors)
Does this mean that Vascepa will be an automatic success in lowering CAD - hardly - from what I recall a recent study on PCSK9-s revealed that the reduction of atherosclerosis was not what was expected for the reduction in LDL . Look at NIacin it raises HDL and HDL was touted as being one of the strongest markers for CAD - no effect on CAD - Zetia initially shown to have no effect on CAD after reducing LDL - repeat study suggested mild benefit .... which of course gets into the whole issue of outcomes studies vs just looking at markers the role of inflammation in CAD etc etc
After practicing medicine for many years one point becomes clear - biological systems are immensely complex - controlling and isolating factors to determine cause and effect is extremely difficult. Whereas , in the electronic, mechanical perhaps even chemical world this is rather easy.
Absence or variation of a gene, resulting in variation in a marker chemical, may not necessarily be the direct correlation we believe it is for disease induction. That gene alteration may be having countless other effects that we are unable to identify - IN many ways we are the blind man who can only feel one part of the elephant - then run out insisting that the elephant is a snake because the only part we felt was the trunk. (Unfortunately, the guy upstairs who made us - never gave us the blueprints).
So this study is great news and perhaps it will lead to the development of a med that has success in lowering the incidence of CAD. However, let me perhaps reflect onto your own experience. WHen you hear about a great breakthrough for cancer - what do you think ?
Currently , I am very jaundiced about such claims - I have heard them for over 30 years. Perhaps there are great breakthroughs in our knowledge and understanding - yet the reality is - cancer has become the #1 killer and our progress is painfully slow as compared to CAD. ( OF course CAD was mainly a plumbing problem - open the pipes - Cancer is so much more complex)
The proof is in the pudding ...and the pudding is still in the oven .......
(dictated with Dragon Dictate excuse errors)
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
